Skip to main content

Mylan receives approval for Parkinson’s disease treatment


PITTSBURGH The Food and Drug Administration has approved a generic version of a drug for Parkinson’s disease.

Mylan announced the approval Wednesday, for its carbidopa and levodopa tablets in the 10 mg/100 mg, 25 mg/100 mg and 25 mg/250 mg strengths.

The tablets are a generic version of Bristol-Myers Squibb’s Sinemet. Branded and generic versions of the drug had sales of $79 million for the 12 months ending June 30, according to IMS Health data.

This ad will auto-close in 10 seconds